Brief: PharmaEssentia Announces Taiwan Approval Of BESREMi For Essential Thrombocythemia
10/06/2026 15:36
BRIEF-PharmaEssentia Announces Taiwan Approval Of BESREMi For Essential Thrombocythemia June 10 (Reuters) - PharmaEssentia Corp 6446.TW:
PHARMAESSENTIA - ANNOUNCES TAIWAN APPROVAL OF BESREMI FOR ESSENTIAL THROMBOCYTHEMIA
PHARMAESSENTIA - U.S. PDUFA DATE REMAINS ON TRACK FOR AUGUST 30, 2026
Source text: ID:nBw3qLYmYa
Further company coverage: 6446.TW
(((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on PHARMAESSENTIA
See all newsBrief: PharmaEssentia Announces Taiwan Approval Of BESREMi For Essential Thrombocythemia
Brief: Pharmaessentia Says Jan-Mar Net Profit T$2.15 Bln
Brief: Pharmaessentia Says To Buy 100% Forus Therapeutics For C$50 Mln
Brief: Pharmaessentia Signs Agreement For New Manufacturing Facility In Puerto Rico
Brief: Pharmaessentia Announces Japan Approval Of High-Dose Dosing Regimen For Besremi